m+Medelevator.RU
← Поиск публикаций
Dermatologic surgery : official publication for American Society for Dermatologic Surgery [et al.] · 2025

Fractional CO 2 Versus Radiofrequency as Hair Regrowth Enhancers for Female Androgenic Alopecia: A Randomized Controlled Trial.

СтатьяРандомизированное исследованиеСравнительное исследованиеНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Hilal Rana F, Shaarawy Eman, Ahmed Nehal, El-Samanoudy Solwan I

Аннотация

BACKGROUND: Androgenic alopecia (AGA) is a cosmetically disfiguring condition, which accounts for most cases of diffuse hair loss among females, negatively impacting their quality of life. Combining Fractional CO 2 (FCO 2 ) or Fractional Microneedling Radiofrequency (FMRF) with topical minoxidil 5% could achieve a better clinical outcome.

OBJECTIVE: To compare efficacy and safety of FCO 2 and FMRF, combined with minoxidil, for the treatment of female AGA.

METHODS: Thirty patients with female AGA were randomly assigned to 2 groups (simple computerized randomization). Group A patients received FCO 2 to 1 randomly selected side of the scalp, and Group B patients received FMRF to 1 randomly selected side of the scalp (picking masked labeled cards). Patients received minoxidil 5%.

RESULTS: Significant increase in trichoscopic hair counts and density was found after treatment with each modality whether minoxidil 5% alone, minoxidil combined with FCO 2 , or minoxidil combined with FMRF. A significantly greater increase in trichoscopic hair counts and density followed the treatment with minoxidil + FMRF, compared to either minoxidil + FCO 2 or minoxidil alone.

CONCLUSION: It can be proposed that combining FMRF with minoxidil for the treatment of female AGA could be associated with higher efficacy and tolerability, compared to the other treatment modalities.

Предметные рубрики MeSH

ИП Урсолов Владлен Сергеевич

ИНН 500118482352 · ОГРНИП 314500117700049

Реквизиты и контакты